Results 91 to 100 of about 8,274 (202)

Hydroxyapatite Nanorods Based Drug Delivery Systems for Bumetanide and Meloxicam, Poorly Water Soluble Active Principles

Nanomaterials
Poorly water-soluble drugs represent a challenge for the pharmaceutical industry because it is necessary to find properly tuned and efficient systems for their release.
Valeria Friuli, Lauretta Maggi, Giovanna Bruni, Francesca Caso, Marcella Bini   +4 more
doaj   +1 more source

Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder

Frontiers in Child and Adolescent Psychiatry
IntroductionAutism spectrum disorder (ASD) is characterised by difficulty with social communication and restricted, repetitive patterns of behaviour. This study aimed to improve understanding of the ASD patient experience with the treatment (bumetanide ...
Natalia Hawken, Bruno Falissard, Carl Choquet, Clement Francois, Jean Tardu, Ramona Schmid   +5 more
doaj   +1 more source

Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimers disease. [PDF]

INTRODUCTION: Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimers disease (AD) based on its effects on transcriptomic apolipoprotein E signatures.
Natarajan, Loki, Hernandez, Inmaculada, Shadyab, Aladdin, LaCroix, Andrea, Feldman, Howard, Morales, Jasmine, Xu, Ronghui, Gabriel, Nico, Silverman, James   +8 more
core   +1 more source

Comparing Loop Diuretics: Furosemide Versus Bumetanide

Loop diuretics are widely used in the treatment of hypertension and edema caused by cardiovascular, renal, and hepatic dysfunction. Furosemide and bumetanide are 2 of the more commonly prescribed loop diuretics.
William H. Frishman, Lucas Dolan, Rithvik Swamynathan, Wilbert S. Aronow   +3 more
core   +1 more source

Development of Acute Tolerance to Bumetanide: Constant-Rate Infusion Studies

, 1988
Bumetanide was administered intravenously to four mongrel dogs as a bolus of 8.7 µg/kg, immediately followed by a constant-rate infusion of 0.35 µg/min/kg at 0.036 ml/min. Treatment A consisted of a 90-min equilibration period and first hour (Phase I) of
Smith, David E., Cook, Jack A.
core   +1 more source

Superfusion of bumetanide blocked the formation of hippocampal LTP in a dose dependent manner.

, 2016
(A) From Left to right, representative superimposed traces of fEPSPs recorded extracellularlly under control conditions and after exposure to 0, 5, 10, and 20 µM bumetanide.
Tamara G. Amstislavskaya (598275), Kwok-Tung Lu (310169), Yi-Ling Yang (310173), Min Chong Lee (2223154), Maria A. Tikhonova (2223157), Meng Chang Ko (2223160)   +5 more
core   +1 more source

A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide

, 2013
Background: The potency of intravenous bumetanide to furosemide using a ratio of 1:40 has been suggested; however, there are little data supporting this ratio.
Nappi,Jean M.
core   +2 more sources

Bumetanide Therapeutic Effect in Children and Adolescents With Autism Spectrum Disorder: A Review Study

Basic and Clinical Neuroscience, 2019
Introduction: Autism Spectrum Disorder (ASD) is characterized by several impairments in communications and social interactions, as well as restricted interests or stereotyped behaviors.
Raheleh Mollajani, Mohamad Taghi Joghataei, Mehdi Tehrani-doost   +2 more
doaj  

Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD

Biomedicines
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a clinically and biologically defined subgroup of patients with Autism Spectrum Disorder (ASD), namely ASD ...
Craig A. Erickson, Laura Perez-Cano, Ernest V. Pedapati, Eric Painbeni, Gregory Bonfils, Lauren M. Schmitt, Hannah Sachs, Meredith Nelson, Lisa De Stefano, Grace Westerkamp, Adriano L. S. de Souza, Oliver Pohl, Offir Laufer, Gil Issachar, Thomas Blaettler, Jean-Marc Hyvelin, Lynn A. Durham   +16 more
doaj   +1 more source

Effects of antihypertensive agents on Alzheimer’s disease biomarkers in hypertensive rats with experimentally induced Alzheimer’s

Zanco Journal of Medical Sciences
Background and objective: The most common cause of dementia in the elderly is Alzheimer's disease (AD). Numerous research studies have demonstrated a connection between hypertension (HTN) and the risk of developing AD.
Marwan Qasim Nadir, Rojgar Hamed Ali
doaj   +1 more source